• 1
    Lindhout D, Meinardi H, Meijer JWA, et al. Antiepileptic drugs and teratogenesis in two consecutive cohorts. Neurology 1992;42(suppl 5):94110.
  • 2
    Kline J, Stein Z, Susser M. Conception to birth: epidemiology of prenatal development. Monogr Epidemiol Biostat 1989;14: 4368.
  • 3
    Kaneko S, Otani K, Kondo T, et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology 1992;42(suppl 5):6874.
  • 4
    Yerby MS. Pregnancy, teratogenesis, and epilepsy. Neurol Clin 1994;12: 74971.
  • 5
    Holmes LB, Harvey BA, Coull KB, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001;344: 11328.
  • 6
    Product information for Lamictal (lamotrigine). http://www. - product information. February 1999.
  • 7
    Sander JW, Patsalos PN. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Res 1992;13: 8992.
  • 8
    Quattrini A, Ortenzi A, Paggi A, et al. Lamotrigine and pregnancy [Letter]. Ital J Neurosci 1996;17: 441.
  • 9
    Rambeck B, Kurlemann G, Stodieck SRG, et al. Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child. Eur J Clin Pharmacol 1997;51: 4814.
  • 10
    Tomson T, Öhman I, Vitols S. Lamotrigine in pregnancy and lactation: a case report. Epilepsia 1997;38: 103941.
  • 11
    Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 2000;41: 70913.
  • 12
    Dravet C, Julian C, Legras C, et al. Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study. Neurology 1992;42(suppl 5):7582.
  • 13
    Battino D, Binelli S, Caccamo ML, et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurol Scand 1992;85: 2047.
  • 14
    Omtzigt JGC, Los JF, Grobbee DE, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992;42(suppl 5):11925.
  • 15
    Samren EB, Van Dujin CM, Christiaens GCML, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999;46: 73946.
  • 16
    Metropolitan Atlanta Congenital Defects Program. In: Surveillance procedure manual and guide to computerized anomaly record. Atlanta: CDC (phone, 770-488-7160), 1998.
  • 17
    Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley & Sons, 1981.
  • 18
    Holmes LB, Kleiner BC, Leppig KA, et al. Predictive value of minor anomalies. II. Use in cohort studies to identify teratogens. Teratology 1987;36: 2917.
  • 19
    Morrow JI, Russell A, Craig JJ, et al. Major malformations in the offspring of women with epilepsy: a comprehensive prospective study. Epilepsia 2001;42(suppl 2):125.
  • 20
    Nelson K, Holmes LB. Malformations due to presumed spontaneous mutations in newborn infants. N Engl J Med 1989;320: 1923.
  • 21
    Mackay FJ, Wilton LV, Pearce GL, et al. Safety of long-term lamotrigine in epilepsy. Epilepsia 1997;38: 8816.
  • 22
    Samren EB, Van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997;38: 98190.
  • 23
    International League Against Epilepsy. Guidelines for the care of women of childbearing age with epilepsy. Epilepsia 1993;34: 5889.
  • 24
    Boyd PA, Chamberlain P, Hicks NR. Six-year experience of prenatal diagnosis in an unselected population in Oxford, UK. Lancet 1998;352: 157781.
  • 25
    DiLiberti JG, Frandon PA, Dennis NR, et al. The fetal valproate syndrome. Am J Med Genet 1984;19: 47381.
  • 26
    Ardinger HH, Atkin JF, Blackston RD, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Genet 1988;29: 17185.